Proposing Vascepa (Icosapent Ethyl) as Supplemental Treatment for Persistent Post-Viral Symptoms of COVID-19: A Case Series

This case series suggests that icosapent ethyl (IPE), a pure esterized form of the omega-3 fatty acid eicosapentaenoic acid (EPA), may be an effective treatment for persistent post-viral symptoms of COVID-19, including post-exertional malaise, cognitive impairment, and dermatologic issues such as hair loss and onycholysis. The patients in the study experienced considerable improvement in their symptoms following IPE treatment. The authors propose that IPE's cell membrane stabilizing, anti-inflammatory, and antithrombotic properties could address the underlying causes of these symptoms, which are thought to be systemic hyperinflammation and hypercoagulation. The study aims to encourage further research into the clinical outcomes of IPE treatment for COVID-19. The document does not specify the number of patients involved in the case series.